Journal: Cancer Cell International

Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

doi: 10.1186/s12935-025-03676-3

Figure Lengend Snippet: Mcl-1 shRNA combined with BCG vaccine may affect the polarization of macrophages toward M1 through the JNK signaling pathway and enhance the efficacy of treating bladder cancer. (A) Immunofluorescence detection of CD86/CD206 protein expression in bladder tissue (scale: 200 μm). (B) Analysis of CD86/CD206 protein expression in bladder tissue. (C) HE staining of bladder tissue of rats in each group. (D) CyclinD1 and PCNA protein band diagrams in bladder cancer tissues of rats in each group. (E , F) Analysis of CyclinD1 and PCNA protein expression in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01 compared with Sham group; # P < 0.05, ## P < 0.01 compared with BLCA group; && P < 0.01 compared with BCG group; $$ P < 0.01 compared with BCG + Mcl-1shRNA group

Article Snippet: Anti-JNK (1:5000, 66210-1-Ig), anti-ASK1 (1:3000, 67072-1-Ig), anti-CX43 (1:4000, 26980-1-AP) were purchased from Proteintech Biotechnology Co., LTD. (Wuhan, China).The following antibodies: Bax (1:1000, bs-4605R), Bcl-2 (1:1000, bsm-52304R), P-ASK1(1:3000, bs-3029R), MKK7 (1:1000, bs-1979R), P-MKK7 (1:300, bs-3277R), P-JNK (1:500, bs-1640R), cJUN (1:1000, bs-0670R), P-cJUN (1:1000, bsm-52141R), CyclinD1 (1:1000, bsm-52046R) and PCNA (1:1000, bsm-52347R), were obtained from Bioss Biotechnology Co., LTD. (Beijing, China).

Techniques: shRNA, Immunofluorescence, Expressing, Staining

Journal: Cancer Cell International

Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

doi: 10.1186/s12935-025-03676-3

Figure Lengend Snippet: Mcl-1 shRNA combined with BCG vaccine may promote the apoptosis of bladder cancer cells by activating the ASK1/MKK7/JNK signaling pathway and enhance the efficacy of treating bladder cancer in rats. (A) Tunel staining of rat bladder tissue in each group (scale: 100 μm). (B) Protein band diagrams of Bax and Bcl-2 in bladder cancer tissues of rats in each group. (C , D) Protein expression analysis of CyclinD1 and PCNA in bladder cancer tissues of rats in each group. (E) Immunohistochemistry detects the expression of P-JNK, P-cJUN, and CX43 in the bladder tissue of rats in each group (scale: 50 μm). (F) cJUN, P-CJUN and CX43 protein band diagrams in bladder cancer tissues of rats in each group. (G) Protein band diagrams of P-JNK and JNK in bladder cancer tissues of rats in each group. (H) Analysis of cJUN and P-CJUN protein expression in bladder cancer tissues of rats in each group. (I) Analysis of JNK and P-JNK protein expression in bladder cancer tissues of rats in each group. (J) CX43 protein expression analysis in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared with BLCA group; & P < 0.05, && P < 0.01, &&& P < 0.001 compared with BCG group; $ P < 0.05, $$ P < 0.01 compared with BCG + Mcl-1shRNA group

Article Snippet: Anti-JNK (1:5000, 66210-1-Ig), anti-ASK1 (1:3000, 67072-1-Ig), anti-CX43 (1:4000, 26980-1-AP) were purchased from Proteintech Biotechnology Co., LTD. (Wuhan, China).The following antibodies: Bax (1:1000, bs-4605R), Bcl-2 (1:1000, bsm-52304R), P-ASK1(1:3000, bs-3029R), MKK7 (1:1000, bs-1979R), P-MKK7 (1:300, bs-3277R), P-JNK (1:500, bs-1640R), cJUN (1:1000, bs-0670R), P-cJUN (1:1000, bsm-52141R), CyclinD1 (1:1000, bsm-52046R) and PCNA (1:1000, bsm-52347R), were obtained from Bioss Biotechnology Co., LTD. (Beijing, China).

Techniques: shRNA, TUNEL Assay, Staining, Expressing, Immunohistochemistry

Journal: FEBS letters

Article Title: Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells.

doi: 10.1016/j.febslet.2004.09.040

Figure Lengend Snippet: Fig. 1. Synthetic DNA sequences. Capital letters in bold indicate sequences from human tRNAtyr gene (A and B). The intron sequence of tRNAtyr (plain capital letters in B) was substituted with a 10 bp oligonucleotide (plain capital letters in A), generating two restriction sites (StuI and BamHI) to ease insertion of any antisenses, not limited to cyclin D1 as in this work. Letters in lower case represent the promoter sequence of U6 SnRNA gene (A), which enhances the transcription efficiency of subsequent pre-tRNA. The U6 SnRNA promoter and the tRNA gene were spaced by two copies of tet operator 2 sequence that serve as the binding sites for two molecules of the Tet repressor protein, so as to block the transcription of pre-tRNA from both U6 SnRNA and tRNA promoters unless with tetracycline inducement.

Article Snippet: For cyclin D1 detection, the sections were hydrated, and probed with an anti-cyclin D1 monoclonal antibody as mentioned above, and then a biotinized anti-mouse antibody and SABC complex (streptavidin–biotin-peroxidase, Boster Biotech, Wuhan, China) in sequence.

Techniques: Sequencing, Binding Assay, Blocking Assay

Journal: FEBS letters

Article Title: Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells.

doi: 10.1016/j.febslet.2004.09.040

Figure Lengend Snippet: Fig. 2. In vitro transcription and splicing of pre-tRNA. With U6 SnRNA promoter, pre-tRNAs in pUT-tyr and pUT-ccnd1 were transcribed more efficiently than pUC-tyr control. The 20 bp anti-cy- clin D1 insert replacing the intron sequence of tRNAtyr gene was correctly spliced out (pUT-ccnd1) as well as the native intron of tRNAtyr gene (pUT-tyr).

Article Snippet: For cyclin D1 detection, the sections were hydrated, and probed with an anti-cyclin D1 monoclonal antibody as mentioned above, and then a biotinized anti-mouse antibody and SABC complex (streptavidin–biotin-peroxidase, Boster Biotech, Wuhan, China) in sequence.

Techniques: In Vitro, Control, Sequencing

Journal: FEBS letters

Article Title: Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells.

doi: 10.1016/j.febslet.2004.09.040

Figure Lengend Snippet: Fig. 3. Western blot analysis of cyclin D1 expression. Stable blastici- din-resistant H22 cell lines were created by transfection with pTRUT- tyr or pTRUT-ccnd1. Both of the two cell lines together with un-transfected H22 control cells were induced with tetracycline for 24 h. Then, cyclin D1 expression was analyzed by Western blot. b-Actin expression was also analyzed as a control. In the figure, cyclin D1 expression was significantly reduced by cyclin D1 antisense RNA. Whereas intron of pre-tRNAtyr generated in the same way had no effect on cyclin D1 expression.

Article Snippet: For cyclin D1 detection, the sections were hydrated, and probed with an anti-cyclin D1 monoclonal antibody as mentioned above, and then a biotinized anti-mouse antibody and SABC complex (streptavidin–biotin-peroxidase, Boster Biotech, Wuhan, China) in sequence.

Techniques: Western Blot, Expressing, Transfection, Control, Generated

Journal: FEBS letters

Article Title: Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells.

doi: 10.1016/j.febslet.2004.09.040

Figure Lengend Snippet: Fig. 6. Immunohistochemical analysis of cyclin D1 expression and apoptosis in s.c. tumor xenografts with and without plasmid pUT-ccnd1 injection. Preformed tumor xenografts were harvested at day 17 after 6 times of plasmid injection. Cyclin D1 expression (A) and apoptosis (B) were analyzed as described in Section 2. (a) s.c. tumors treated with TE only; (b) s.c. tumors treated with plasmid pUT-ccnd1.

Article Snippet: For cyclin D1 detection, the sections were hydrated, and probed with an anti-cyclin D1 monoclonal antibody as mentioned above, and then a biotinized anti-mouse antibody and SABC complex (streptavidin–biotin-peroxidase, Boster Biotech, Wuhan, China) in sequence.

Techniques: Immunohistochemical staining, Expressing, Plasmid Preparation, Injection

Journal: FEBS letters

Article Title: Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells.

doi: 10.1016/j.febslet.2004.09.040

Figure Lengend Snippet: Fig. 5. Effect of plasmid administration on tumor growth. Four days after inoculation of H22 cells (Day 5), pUT-ccnd1 plasmid was injected into the s.c. tumor xenografts at multiple sites until day 11 or day 15. Tumor volumes were determined by bidimensional caliper measure- ments and were presented as the mean tumor volume (n ¼ 8). The bars stand for standard deviation. (*) Significant (P < 0:05) volume differ- ence between plasmid treated tumors and TE treated control tumors. ðmÞ Significant (P < 0:05) difference between short-term plasmid treated tumors (to day 11) and long-term treated tumors (to day 15). Fig. 4. Cell proliferation assay by MTT method. H22 cells were stained by MTT. Proliferation of the cells was significantly (P < 0:05) reduced by the antisense RNA. The bars represent the standard deviations calculated from three repeated experiments.

Article Snippet: For cyclin D1 detection, the sections were hydrated, and probed with an anti-cyclin D1 monoclonal antibody as mentioned above, and then a biotinized anti-mouse antibody and SABC complex (streptavidin–biotin-peroxidase, Boster Biotech, Wuhan, China) in sequence.

Techniques: Plasmid Preparation, Injection, Standard Deviation, Control, Proliferation Assay, Staining

Journal: Radiology and Oncology

Article Title: Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy

doi: 10.2478/raon-2014-0048

Figure Lengend Snippet: Antibodies and preconditioning applied for immunohistochemistry

Article Snippet: Ciklin D1 , P2D11F11 , Novocastra , 1:10 , MW , 6 min, EDTA buffer, pH 8.0 cooling 10 min .

Techniques:

Journal: Middle East Journal of Digestive Diseases

Article Title: Expression of Cyclin D1 and P16 in Esophageal Squamous Cell Carcinoma

doi:

Figure Lengend Snippet: Distribution of variables in 30 cases of ESCC by cyclin D1 status

Article Snippet: The paraffin embedded sections of the tumor were stained by a monoclonal antibody raised against cyclin D1 (Biogenex, CA, USA) and p16 (Biogenex, CA, USA).

Techniques: